Table S5.
Treatment response rates of ranibizumab and bevacizumab for the treatment of age-related macular degeneration
| Author | Year | Definition of treatment response | IVR | IVB | RR (95% CI) | ||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| No of responses | No of nonresponses | No of responses | No of nonresponses | ||||
| Martin et al25 | 2011 | 15-letter increase in ETDRS score | 71 | 214 | 76 | 195 | 0.89 (0.67–1.17) |
| Gharbiya et al24 | 2010 | 15-letter increase in ETDRS score | 9 | 7 | 10 | 6 | 0.90 (0.51–1.60) |
| Biswas et al23 | 2011 | 15-letter increase in ETDRS score | 7 | 47 | 3 | 47 | 2.15 (0.59–7.90) |
| Subramanian et al26 | 2009 | 15-letter increase in ETDRS score | 1 | 6 | 5 | 10 | 0.43 (0.05–3.01) |
| Pooled RR (95% CI) | 0.91 (0.71–1.16) | ||||||
Abbreviations: CI, confidence interval; IVB, intravitreal bevacizumab; PDT, photodynamic therapy; RR, relative risk; ETDRS, Early Treatment Diabetic Retinopathy Study.